The Filing Desk

ABVC BioPharma vs Tenax Therapeutics

ABVC BioPharma ABVC · Tenax Therapeutics TENX · Pharmaceuticals

Side by side

ABVC BioPharmaTenax Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$0M$0M
Revenue growth−41.9%—
Revenue growth a year, last 5 years−9.7%—
Gross margin——
Operating margin−2,416.0%—
Net margin−2,671.8%—
Free cash flow——
Free cash flow margin——
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count72.2%156.8%
Last close$0.88$1.39
P/E at the last close——
Insider trades, last 12 months—bought $5.0 million, sold $0
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ABVC BioPharmaTenax Therapeutics
Operating margin
Percent of revenue
ABVC BioPharmaTenax Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ABVC BioPharmaTenax Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ABVC BioPharma and Tenax Therapeutics pages.